Overview
- Dassault Systèmes announced on July 23, 2026 that it will buy ArisGlobal from Nordic Capital for $1.8 billion up front plus up to $200 million in earnouts tied to future AI revenue.
- The company said it expects to complete the transaction in the second half of 2026 and will fold ArisGlobal’s regulatory, pharmacovigilance and medical‑record monitoring platform into its software portfolio.
- Dassault reported a 28% rise in first‑half net profit to €611.8 million the same day and kept its full‑year revenue growth guidance, framing the deal as a strategic move to grow its life‑sciences business.
- ArisGlobal is a specialist with about 1,300 employees that serves large biopharma clients and produces millions of patient‑safety reports a year while targeting roughly $175 million in revenue for 2026.
- Because $200 million of the price depends on AI revenue milestones, Dassault is tying part of the price to ArisGlobal’s future AI performance, a structure that links valuation to the technology’s commercial uptake.